These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26486517)

  • 1. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
    Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
    Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
    Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
    Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
    Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
    Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
    Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
    Oncologist; 2012; 17(4):512. PubMed ID: 22416063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
    Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
    Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
    Pusztai L; Wagner P; Ibrahim N; Rivera E; Theriault R; Booser D; Symmans FW; Wong F; Blumenschein G; Fleming DR; Rouzier R; Boniface G; Hortobagyi GN
    Cancer; 2005 Aug; 104(4):682-91. PubMed ID: 15986399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
    Tambaro R; Greggi S; Iaffaioli RV; Rossi A; Pisano C; Manzione L; Ferrari E; Di Maio M; Iodice F; Casella G; Laurelli G; Pignata S
    Ann Oncol; 2003 Sep; 14(9):1406-11. PubMed ID: 12954580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Leu KM; Kim KM; Larson M; Larson M; Schiller JH
    Lung Cancer; 2001 Oct; 34(1):105-13. PubMed ID: 11557120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
    Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in combination with doxorubicin or vinorelbine.
    Diéras V; Fumoleau P; Kalla S; Misset JL; Azli N; Pouillart P
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S20-2. PubMed ID: 9486099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Acta Oncol; 2003; 42(3):186-94. PubMed ID: 12852694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
    Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
    Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
    Fox E; Bates SE
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.